Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$55.45 USD
+1.13 (2.08%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.45 USD
+1.13 (2.08%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Zacks News
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.
Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.
Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
by Zacks Equity Research
Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.
Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
by Arpita Dutt
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
Bristol Myers' Future Unsure as Carl Icahn Takes Stake
by Joseph Lu
Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Can Carl Icahn Save Bristol Myers Squibb?
by Joseph Lu
Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
by Arpita Dutt
The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.
Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
by Arpita Dutt
Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.
Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints
by Zacks Equity Research
Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.
Q4 Earnings Faring Well for Pharma ETFs
by Sweta Killa
Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.
Portola, HealthCare Royalty Partners Ink $150 Million Deal
by Zacks Equity Research
Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.
Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo
Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling
by Arpita Dutt
Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).
Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales
by Zacks Equity Research
Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.
Implied Volatility Surging for Bristol-Myers Squibb Co. (BMY) Stock Options
by Zacks Equity Research
Bristol-Myers Squibb Co. (BMY) warrants investors' attention based on moves in the options market lately.
Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE
by Zacks Equity Research
Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.
Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint
by Arpita Dutt
Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.
Bristol-Myers (BMY) Misses on Q4 Earnings, Beats on Sales
by Zacks Equity Research
Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.
Bristol-Myers (BMY) Q4 Earnings Miss Estimates
by Zacks Equity Research
Bristol-Myers (BMY) reported fourth quarter earnings of 63 cents on revenues of $5.23 billion.